Covid-19: Bharat Biotech's Covaxin, Serum Institute's Covishield vaccines get 'Conditional Market Authorization' approval form DCGI - details here!
DCGI on Thursday gave its nod for market authorization of two COVID-19 vaccines - Covaxin and Covishield subject to certain conditions. Consent came after the the Subject Expert Committee of CDSCO recommended for upgradation of status for vaccines from restricted use in emergency situations to grant of new drug permission
India's national drug reguator on Thursday gave its nod for market authorization of two COVID-19 vaccines - Covaxin and Covishield subject to certain conditions. The Director Controller General of India (DCGI) consent came after the the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) had recommended for upgradation of status for the vaccines from restricted use in emergency situations to grant of new drug permission with conditions in the adult population on 19 January 2022.
'Conditional Market Authorization' is a new category of market authorization that has emerged during the current global pandemic of COVID19. The approval pathways through this route are fast-tracked with certain conditions to enhance the access to certain pharmaceuticals for meeting the emerging needs of drugs or vaccines.
See Zee Business Live TV Streaming Below:
The market authorization of two COVID19 vaccines, Covaxin and Covishield, in the country by DCGI is subject to the following conditions:
1. Firm shall submit data of overseas ongoing clinical trials of the product with due analysis on six monthly basis or as and when available, whichever is earlier.
2. The vaccine shall be supplied for programmatic setting and all vaccinations done within the country to be recorded on CoWIN platform and Adverse Event Following Immunization [AEFI], Adverse Event of
While Covaxin has been developed by Bharat Biotech Limited, Covishield has been developed by Serum Institute of India (SII).
Special Interest [AESI] shall continue to be monitored. The firms will submit the safety data including AEFI and AESI with due analysis on six monthly basis or as and when available, whichever is earlier as per NDCT Rules, 2019.
The proactive and agile approach followed by Government of India has been a hallmark of its strategy of management of COVID19. The latest approval accorded by DCGI for conditional market authorization to two COVID19 vaccines in the country indicates the promptness and timeliness with which the public response strategy and decision making apparatus of the country has responded to the emerging needs during the pandemic.
It may be noted that of the global Stringent Regulatory Authorities, only the United States Food and Drug Administration (USFDA) Medicines and Healthcare products Regulatory Agency (MHRA) of the UK have granted “conditional market authorization” to Pfizer and AstraZeneca, respectively, for their COVID19 Vaccines.
India’s nation-wide COVID19 vaccination program was launched on 16th January, 2021. As of today, more than 160 crore doses have been administered. The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country. New categories of population have been added to the national COVID19 vaccination drive starting from 3rd January 2022.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
IRCTC Dividend 2024: Railway PSU announces 200% interim dividend - Check record date and other details
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
06:16 PM IST